The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation
Open accessAbstract
Objectives This study sought to assess the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with atrial fibrillation (AF) enrolled in the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) trial, and the treatment effect of apixaban according to NT-proBNP levels.Background Natriuretic peptides are associated with mortality and cardiovascular events in several cardiac diseases.Methods In the ARISTOTLE trial, 18,201 patients with AF were randomized to apixaban or warfarin. Plasma samples at randomization were available from 14,892 patients. The association between NT-proBNP concentrations and clinical outcomes was evaluated using Cox proportional hazard models, after adjusting for established cardiovascular risk factors.Results Quartiles of NT-proBNP were: Q1, ≤363 ng/l; Q2, 364 to 713 ng/l; Q3, 714 to 1,250 ng/l; and Q4, >1,250 ng/l. During 1.9 years, the annual rates of stroke or systemic embolism ranged from 0.74% in the bottom NT-proBNP quartile to 2.21% in the top quartile, an adjusted hazard ratio of 2.35 (95% confidence interval [CI]: 1.62 to 3.40; p < 0.0001). Annual rates of cardiac death ranged from 0.86% in Q1 to 4.14% in Q4, with an adjusted hazard ratio of 2.50 (95% CI: 1.81 to 3.45; p < 0.0001). Adding NT-proBNP levels to the CHA2DS2VASc score improved C-statistics from 0.62 to 0.65 (p = 0.0009) for stroke or systemic embolism and from 0.59 to 0.69 for cardiac death (p < 0.0001). Apixaban reduced stroke, mortality, and bleeding regardless of the NT-proBNP level.Conclusions NT-proBNP levels are often elevated in AF and independently associated with an increased risk of stroke and mortality. NT-proBNP improves risk stratification beyond the CHA2DS2VASc score and might be a novel tool for improved stroke prediction in AF. The efficacy of apixaban compared with warfarin is independent of the NT-proBNP level. (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation [ARISTOTLE]; NCT00412984).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Measurement of cardiac troponin (high-sensitivity troponin T or I) and N-terminal pro-B-type natriuretic peptide may provide additional prognostic information in selected AF patients.[380][381][382]”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [381]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,924
Impact of Atrial Fibrillation on the Risk of Death: The Framingham Heart Study
Benjamin, E. J., Wolf, P. A., D’Agostino, R. B., Silbershatz, H., Kannel, W. B., & Levy, D. (1998) · Circulation · doi:10.1161/01.cir.98.10.946 · Cited by 4,575
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · CHEST Journal · doi:10.1378/chest.10-0134 · Cited by 4,517
Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death
Wang, T. J., Larson, M. G., Levy, D. A., Benjamin, E. J., Leip, E. P., Omland, T., Wolf, P. A., & Vasan, R. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031994 · Cited by 1,521
Cited by
Sorted by citations
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P. F., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellà, M., Diener, H., Heidbüchel, H., Hendriks, J., et al. (2016) · EP Europace · doi:10.1093/europace/euw295 · Cited by 6,438
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403
Goetze, J. P., Bruneau, B. G., Ramos, H. R., Ogawa, T., de Bold, M. L. K., & de Bold, A. J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0381-0 · Cited by 572
Hijazi, Z., Oldgren, J., Lindbäck, J., Alexander, J. H., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Held, C., Hylek, E. M., Lopes, R. D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00741-8 · Cited by 490
Hijazi, Z., Lindbäck, J., Alexander, J. H., Hanna, M., Held, C., Hylek, E. M., Lopes, R. D., Oldgren, J., Siegbahn, A., Stewart, R. A. H., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw054 · Cited by 437
Wallentin, L. C., Hijazi, Z., Andersson, U., Alexander, J. H., Caterina, R. D., Hanna, M., Horowitz, J. D., Hylek, E. M., Lópes, R. D., Åsberg, S., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.011204 · Cited by 310
Shen, M. J., Arora, R., & Jalife, J. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.05.005 · Cited by 243
Sandhu, R. K., Ezekowitz, J. A., Andersson, U., Alexander, J. H., Granger, C. B., Halvorsen, S., Hanna, M., Hijazi, Z., Janský, P., Lópes, R. D., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw124 · Cited by 235
Digoxin and Mortality in Patients With Atrial Fibrillation
Lópes, R. D., Rordorf, R., Ferrari, G. M. D., Leonardi, S., Thomas, L. E., WOJDYLA, D. M., Ridefelt, P., Lawrence, J. H., Caterina, R. D., Vinereanu, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.060 · Cited by 218
Novel biomarkers of cardiovascular disease: Applications in clinical practice
Lyngbakken, M. N., Myhre, P. L., Røsjø, H. R., & Omland, T. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1525335 · Cited by 155
Kirchhof, P. F., BREITHARDT, G. E., Bax, J. J., Benninger, G., Blomström‐Lundqvist, C., Boriani, G., Brandes, A., Brown, H., Brueckmann, M., Calkins, H. G., et al. (2015) · EP Europace · doi:10.1093/europace/euv304 · Cited by 143
Kimachi, M., Furukawa, T. A., Kimachi, K., Goto, Y., Fukuma, S., & Fukuhara, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011373.pub2 · Cited by 144
Berg, D. D., Ruff, C. T., Jarolı́m, P., Giugliano, R. P., Nordio, F., Lanz, H., Mercuri, M. F., Antman, E. M., D, E. B. M., & Morrow, D. A. (2019) · Circulation · doi:10.1161/circulationaha.118.038312 · Cited by 138
Hijazi, Z., Oldgren, J., Lindbäck, J., Alexander, J. H., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Held, C., Hylek, E. M., Lópes, R. D., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx584 · Cited by 122
Wallentin, L. C., Lindbäck, J., Eriksson, N., Hijazi, Z., Eikelboom, J. W., Ezekowitz, M. D., Granger, C. B., Lópes, R. D., Yusuf, S., Oldgren, J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa697 · Cited by 124
Atrial Fibrillation and Ischemic Stroke: A Clinical Review
Migdady, I., Russman, A., & Buletko, A. B. (2021) · Seminars in Neurology · doi:10.1055/s-0041-1726332 · Cited by 130
Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy
Calenda, B. W., Fuster, V., Halperin, J. L., & Granger, C. B. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.106 · Cited by 117
Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation
Abdul‐Rahim, A. H., Moreno, A. C. P., Fulton, R. L., Jhund, P. S., Latini, R., Tognoni, G., Wikstrand, J., KJEKSHUS, J. K., Lip, G. Y. H., Maggioni, A. P., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013760 · Cited by 114
Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation
Oldgren, J., Hijazi, Z., Lindbäck, J., Alexander, J. H., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Granger, C. B., Hylek, E. M., Lópes, R. D., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.022802 · Cited by 107
Ischemic Stroke Risk in Patients With Nonvalvular Atrial Fibrillation
Alkhouli, M. A., & Friedman, P. A. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.040 · Cited by 104
Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation
Hijazi, Z., Oldgren, J., Siegbahn, A. G., & Wallentin, L. C. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.255182 · Cited by 104
Zhu, W., Wan, R., Liu, F., Hu, J., Huang, L., Li, J., & Hong, K. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004006 · Cited by 97
Hijazi, Z., Aulin, J., Andersson, U., Alexander, J. H., Gersh, B. J., Granger, C. B., Hanna, M., Horowitz, J. D., Hylek, E. M., Lópes, R. D., et al. (2016) · Heart · doi:10.1136/heartjnl-2015-308887 · Cited by 94
Brain-heart axis--Review Article.
Manea, M. M., Comsa, M., Mincă, A., Dragoș, D., & Popa, C. (2015) · Europe PMC (PubMed Central) · Cited by 90
Pol, T., Held, C., Westerbergh, J., Lindbäck, J., Alexander, J. H., Alings, M., Erol, Ç., Goto, S., Halvorsen, S., Huber, K., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007444 · Cited by 89
The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal
Esteve‐Pastor, M. A., Roldán, V., Rivera‐Caravaca, J. M., Ramírez-Macías, I., Lip, G. Y. H., & Marín, F. R. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1696955 · Cited by 82
Biological significance of miR-126 expression in atrial fibrillation and heart failure
Wei, X. J., Han, M., Yang, F. Y., Wei, G., Liang, Z. G., Yao, H., Ji, C., Xie, R. S., Gong, C., & Tian, Y. (2015) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20154590 · Cited by 72
Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation
Ruff, C. T., Giugliano, R. P., D, E. B. M., Murphy, S. A., Brown, K. S., Jarolı́m, P., Mercuri, M. F., Antman, E. M., & Morrow, D. A. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.3311 · Cited by 71
Stratifying Stroke Risk in Atrial Fibrillation
Yaghi, S. R., & Kamel, H. (2017) · Stroke · doi:10.1161/strokeaha.117.017084 · Cited by 69
Wu, N., Chen, X., Cai, T., Wu, L., Xiang, Y., Zhang, M., Li, Y., Song, Z., & Zhong, L. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.12.002 · Cited by 70
Lip, G. Y. H., Skjøth, F., Nielsen, P. B., Kjældgaard, J. N., & Larsen, T. B. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.11.046 · Cited by 67
Rivera‐Caravaca, J. M., Marín, F. R., Vilchez, J. A., Gálvez, J., Esteve‐Pastor, M. A., Vicente, V., Lip, G. Y. H., & Roldán, V. (2019) · Stroke · doi:10.1161/strokeaha.118.024305 · Cited by 62
Svennberg, E., Lindahl, B., Berglund, L., Eggers, K. M., Venge, P., Zethelius, B., Rosenqvist, M., Lind, L., & Hijazi, Z. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.08.001 · Cited by 60
Siegbahn, A., Oldgren, J., Andersson, U., Ezekowitz, M. D., Reilly, P. A., Connolly, S. J., Yusuf, S., Wallentin, L. C., & Eikelboom, J. W. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-07-0529 · Cited by 58
Ogata, T., Matsuo, R., Kiyuna, F., Hata, J., Ago, T., Tsuboi, Y., Kitazono, T., Kamouchi, M., Ibayashi, S., Kusuda, K., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006402 · Cited by 60
Hess, P. L., Mirro, M. J., Diener, H., Eikelboom, J. W., Al‐Khatib, S. M., Hylek, E. M., Bosworth, H. B., Gersh, B. J., Singer, D. E., Flaker, G., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.04.007 · Cited by 58
Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy
Hijazi, Z., Oldgren, J., Andersson, U., Connolly, S. J., Ezekowitz, M. D., Hohnloser, S. H., Reilly, P. A., Siegbahn, A., Yusuf, S., & Wallentin, L. C. (2014) · Heart · doi:10.1136/heartjnl-2013-304872 · Cited by 53
Biomarkers in heart failure with preserved ejection fraction
Meijers, W. C., van der Velde, A. R., & de Boer, R. A. (2016) · Netherlands Heart Journal · doi:10.1007/s12471-016-0817-7 · Cited by 56
Hijazi, Z., Oldgren, J., Andersson, U., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Reilly, P. A., Yusuf, S., Siegbahn, A., & Wallentin, L. C. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.06.001 · Cited by 53
van der Endt, V. H. W., Milders, J., de Vries, B. B. L. P., Trines, S. A. I. P., Groenwold, R. H. H., Dekkers, O. M., Trevisan, M., Carrero, J. J., van Diepen, M., Dekker, F. W., et al. (2022) · EP Europace · doi:10.1093/europace/euac096 · Cited by 54
Hijazi, Z., Benz, A. P., Lindbäck, J., Alexander, J. H., Connolly, S. J., Eikelboom, J. W., Granger, C. B., Kastner, P., Lópes, R. D., Ziegler, A., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac632 · Cited by 52
Benz, A. P., Hijazi, Z., Lindbäck, J., Connolly, S. J., Eikelboom, J. W., Oldgren, J., Siegbahn, A. G., & Wallentin, L. C. (2021) · Circulation · doi:10.1161/circulationaha.120.053100 · Cited by 54
Brady, P., Chua, W., Neháj, F., Connolly, D. L., Khashaba, A., Purmah, Y., Qamar, M. J. U., Thomas, M. R., Varma, C., Schnabel, R. B., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.022833 · Cited by 49
Camelo-Castillo, A. J., Rivera‐Caravaca, J. M., Marín, F. R., Vicente, V., Lip, G. Y. H., & Roldán, V. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1712914 · Cited by 48
Roldán, V., Vilchez, J. A., Manzano‐Fernández, S., Jover, E., Gálvez, J., Puche, C. M., Valdés, M., Vicente, V., Lip, G. Y. H., & Marín, F. R. (2014) · Stroke · doi:10.1161/strokeaha.113.003338 · Cited by 47
Biomarkers in atrial fibrillation: an overview
Vilchez, J. A., Roldán, V., Hernández‐Romero, D., Valdés, M., Lip, G. Y. H., & Marín, F. R. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12304 · Cited by 47
Rivera‐Caravaca, J. M., Roldán, V., Esteve‐Pastor, M. A., Valdés, M., Vicente, V., Lip, G. Y. H., & Marín, F. R. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006490 · Cited by 47
Clinical Applications of Biomarkers in Atrial Fibrillation
Chang, K., Hsu, J. C., Toomu, A., Fox, S., & Maisel, A. S. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.08.003 · Cited by 49
Risk stratification for stroke in atrial fibrillation: a critique
Killu, A. M., Granger, C. B., & Gersh, B. J. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy731 · Cited by 50
Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation
Sharma, A., Hijazi, Z., Andersson, U., Al‐Khatib, S. M., Lópes, R. D., Alexander, J. H., Held, C., Hylek, E. M., Leonardi, S., Hanna, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034125 · Cited by 46
Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis
Beggs, S. A. S., Rørth, R., Gardner, R. S., & McMurray, J. J. V. (2019) · Heart · doi:10.1136/heartjnl-2018-314381 · Cited by 49
Buttner, P. G., Schumacher, K., Dinov, B., Zeynalova, S., Sommer, P., Bollmann, A., Husser, D., Hindricks, G., & Kornej, J. (2018) · Heart Rhythm · doi:10.1016/j.hrthm.2018.03.021 · Cited by 45
Biomarkers for Risk Assessment in Atrial Fibrillation
Berg, D. D., Ruff, C. T., & Morrow, D. A. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa298 · Cited by 45
Pol, T., Hijazi, Z., Lindbäck, J., Oldgren, J., Alexander, J. H., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Granger, C. B., Lópes, R. D., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab262 · Cited by 45
Prediction of electro-anatomical substrate using APPLE score and biomarkers
Kornej, J., Buttner, P. G., Sommer, P., Dagres, N., Dinov, B., Schumacher, K., Bollmann, A., & Hindricks, G. (2018) · EP Europace · doi:10.1093/europace/euy120 · Cited by 44
Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation
Baba, M., Yoshida, K., & Ieda, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112824 · Cited by 44
B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation
Inohara, T., Kim, S., Pieper, K. S., Blanco, R. G., Allen, L. A., Fonarow, G. C., Gersh, B. J., Ezekowitz, M. D., Kowey, P. R., Reiffel, J. A., et al. (2018) · Heart · doi:10.1136/heartjnl-2018-313642 · Cited by 42
Biomarkers in Atrial Fibrillation
Noubiap, J. J., Sanders, P., Nattel, S., & Lau, D. H. (2021) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2020.10.006 · Cited by 41
Natriuretic peptides: biomarkers for atrial fibrillation management
Shamloo, A. S., Bollmann, A., Dagres, N., Hindricks, G., & Arya, A. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01608-x · Cited by 38
Hennings, E., Blum, S., Aeschbacher, S., Coslovsky, M., Knecht, S., Eken, C., Lischer, M., Paladini, R. E., Krisai, P., Reichlin, T., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028255 · Cited by 37
Xing, L. Y., Diederichsen, S. Z., Højberg, S., Krieger, D. W., Graff, C., Frikke‐Schmidt, R., OLESEN, M. S., Brandes, A., Køber, L., Haugan, K., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.064361 · Cited by 37
Gudmundsdottir, K. K., Svennberg, E., Friberg, L., Hygrell, T., Frykman, V., Al‐Khalili, F., Hijazi, Z., Rosenqvist, M., & Engdahl, J. (2024) · Circulation · doi:10.1161/circulationaha.124.071176 · Cited by 36
Iguchi, M., Tezuka, Y., Ogawa, H., Hamatani, Y., Takagi, D., An, Y., Unoki, T., Ishii, M., Masunaga, N., Esato, M., et al. (2018) · Circulation Journal · doi:10.1253/circj.cj-17-1155 · Cited by 36
Shin, S. Y., Han, S. J., Kim, J. S., Im, S. I., Shim, J., Ahn, J., Lee, E. M., Park, Y. M., Kim, J. H., Lip, G. Y. H., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012697 · Cited by 36
García-Fernández, A., Roldán, V., Rivera‐Caravaca, J. M., Hernández‐Romero, D., Valdés, M., Vicente, V., Lip, G. Y. H., & Marín, F. R. (2017) · Scientific Reports · doi:10.1038/srep41565 · Cited by 35
Ding, W. Y., Harrison, S. L., Gupta, D., Lip, G. Y. H., & Lane, D. A. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00054 · Cited by 36
N-terminal pro B-type natriuretic peptide in systematic screening for atrial fibrillation
Svennberg, E., Henriksson, P., Engdahl, J., Hijazi, Z., Al‐Khalili, F., Friberg, L., & Frykman, V. (2017) · Heart · doi:10.1136/heartjnl-2016-310236 · Cited by 33
Zhang, J., Lenarczyk, R., Marín, F. R., Małaczyńska-Rajpold, K., Kosiuk, J., Doehner, W., Gelder, I. C. V., Lee, G., Hendriks, J., Lip, G. Y. H., et al. (2020) · EP Europace · doi:10.1093/europace/euaa358 · Cited by 32
The changing circumstance of atrial fibrillation ‐ progress towards precision medicine
Camm, A. J., Savelieva, I., Potpara, T., Hindriks, G., Pison, L., & Blomström‐Lundqvist, C. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12478 · Cited by 30
Hess, P. L., Healey, J. S., Granger, C. B., Connolly, S. J., Ziegler, P., Alexander, J. H., Kowey, P. R., Ruff, C. T., Flaker, G., Halperin, J. L., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.5167 · Cited by 32
Hijazi, Z., Lindahl, B., Oldgren, J., Andersson, U., Lindbäck, J., Granger, C. B., Alexander, J. H., Gersh, B. J., Hanna, M., Harjola, V., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004851 · Cited by 31
Kerr, B., & Brandon, L. (2022) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2022.101132 · Cited by 34
Bernhardt, A. M., Tiedt, S., Teupser, D., Dichgans, M., Meyer, B., Gempt, J., Kuhn, P., Simons, M., Palleis, C., Weidinger, E., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104456 · Cited by 32
Risk prediction of atrial fibrillation in the community combining biomarkers and genetics
Börschel, C. S., Ohlrogge, A. H., Geelhoed, B., Niiranen, T., Havulinna, A. S., Palosaari, T., Jousilahti, P., Rienstra, M., van der Harst, P., Blankenberg, S., et al. (2020) · EP Europace · doi:10.1093/europace/euaa334 · Cited by 31
Multiple Blood Biomarkers and Stroke Risk in Atrial Fibrillation: The REGARDS Study
Singleton, M. J., Yuan, Y., Dawood, F. Z., Howard, G., Judd, S. E., Zakai, N. A., Howard, V. J., Herrington, D. M., Soliman, E. Z., & Cushman, M. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020157 · Cited by 29
Serum Neurofilament Light Chain in Patients With Atrial Fibrillation
Sjölin, K., Aulin, J., Wallentin, L. C., Eriksson, N., Held, C., Kultima, K., Oldgren, J., & Burman, J. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025910 · Cited by 28
Vinereanu, D., Lópes, R. D., Mulder, H. S., Gersh, B. J., Hanna, M., Silva, P. G. M. D. B. E., Atar, D., Wallentin, L. C., Granger, C. B., & Alexander, J. H. (2017) · Stroke · doi:10.1161/strokeaha.117.017574 · Cited by 28
Prognostic significance of natriuretic peptide levels in atrial fibrillation without heart failure
Hamatani, Y., Iguchi, M., Ueno, K., Aono, Y., Esato, M., Tsuji, H., Wada, H., Hasegawa, K., Ogawa, H., Abe, M., et al. (2020) · Heart · doi:10.1136/heartjnl-2020-317735 · Cited by 27
Matusik, P. T., Matusik, P. S., Kornacewicz‐Jach, Z., Małecka, B., Ząbek, A., & Undas, A. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.05.060 · Cited by 26
Roldán, V., Rivera‐Caravaca, J. M., Shantsila, A., García-Fernández, A., Esteve‐Pastor, M. A., Vilchez, J. A., Romera, M., Valdés, M., Vicente, V., Marín, F. R., et al. (2017) · Annals of Medicine · doi:10.1080/07853890.2017.1378429 · Cited by 26
Cha, M., Lee, H. S., Kim, H. M., Jung, J.-H., Choi, E., & Oh, S. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.07.028 · Cited by 28
North American Thrombosis Forum, AF Action Initiative Consensus Document
Ruff, C. T., Ansell, J., Becker, R. C., Benjamin, E. J., Deicicchi, D. J., Estes, N. A. M., Ezekowitz, M. D., Fanikos, J. R., Fareed, J., Garcia, D. A., et al. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.02.001 · Cited by 24
Aggarwal, P., Jamshed, N., & Galwankar, S. (2014) · International Journal of Critical Illness and Injury Science · doi:10.4103/2229-5151.141406 · Cited by 25
Aulin, J., Hijazi, Z., Lindbäck, J., Alexander, J. H., Gersh, B. J., Granger, C. B., Hanna, M., Horowitz, J. D., Lópes, R. D., McMurray, J. J. V., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.03.009 · Cited by 24
Pedro, B., Mavropoulou, A., Oyama, M. A., Linney, C., Neves, J., Dukes‐McEwan, J., Fontes-Sousa, A. P., & Gelzer, A. R. (2023) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.16666 · Cited by 24
Aulin, J., Hijazi, Z., Siegbahn, A. G., Andersson, U., Alexander, J. H., Connolly, S. J., Ezekowitz, M. D., Gersh, B. J., Granger, C. B., Horowitz, J. D., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14947 · Cited by 24
Cardiac biomarkers predict mortality in emergency patients presenting with atrial fibrillation
Niederdöckl, J. D., Simon, A., Schnaubelt, S., Schuetz, N., Laggner, R., Sulzgruber, P., Spiel, A. O., Herkner, H., Laggner, A. N., & Domanovits, H. (2018) · Heart · doi:10.1136/heartjnl-2018-313145 · Cited by 23
Hijazi, Z., Verdecchia, P., Oldgren, J., Andersson, U., Reboldi, G., Pasquale, G. D., Mazzotta, G., Angeli, F., Eikelboom, J. W., Ezekowitz, M. D., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010107
Bening, C., Mazalu, E.-A., Yaqub, J., Alhussini, K., Glanowski, M., Kottmann, T., & Leyh, R. G. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.02.068 · Cited by 22
Wakula, P., Neumann, B., Kienemund, J., Thon-Gutschi, E., Stojaković, T., Manninger, M., Scherr, D., Scharnagl, H., Kapl, M., Pieske, B. M., et al. (2016) · EP Europace · doi:10.1093/europace/euw101 · Cited by 21
Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation
Aulin, J., Sjölin, K., Lindbäck, J., Benz, A. P., Eikelboom, J. W., Hijazi, Z., Kultima, K., Oldgren, J., Wallentin, L. C., Burman, J., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069440 · Cited by 20
Sandhu, R. K., Ezekowitz, J. A., Hijazi, Z., Westerbergh, J., Aulin, J., Alexander, J. H., Granger, C. B., Halvorsen, S., Hanna, M. S., Lópes, R. D., et al. (2018) · Open Heart · doi:10.1136/openhrt-2018-000908 · Cited by 20
Wijsman, L. W., Sabayan, B., van Vliet, P., Trompet, S., de Ruijter, W., Poortvliet, R. K. E., van Peet, P. G., Gussekloo, J., Jukema, J. W., Stott, D. J., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24203 · Cited by 21
Holl, M. J., van den Bos, E. J., van Domburg, R. T., Fouraux, M. A., & Kofflard, M. J. M. (2018) · Clinical Cardiology · doi:10.1002/clc.22883 · Cited by 19
Sweeney, C. M., Ryan, F., Ledwidge, M. T., Ryan, C. A., McDonald, K., Watson, C. J., Pharithi, R. B., & Gallagher, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013015.pub2 · Cited by 16
Rivera‐Caravaca, J. M., Roldán, V., Romera, M., Esteve‐Pastor, M. A., Valdés, M., Lip, G. Y. H., Vicente, V., & Marín, F. R. (2018) · Journal of General Internal Medicine · doi:10.1007/s11606-017-4279-4 · Cited by 17
Plasma Proteomic Associations With Incident Ischemic Stroke in Older Adults
Kalani, R., Bartz, T. M., Psaty, B. M., Elkind, M. S. V., Floyd, J. S., Gerszten, R. E., Shojaie, A., Heckbert, S. R., Bis, J. C., Austin, T. R., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207242 · Cited by 17
Gkarmiris, K. I., Lindbäck, J., Alexander, J. H., Granger, C. B., Kastner, P., Lópes, R. D., Ziegler, A., Oldgren, J., Siegbahn, A. G., Wallentin, L. C., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033720 · Cited by 16
Nakamura, M., Koeda, Y., Tanaka, F., Onoda, T., Itai, K., Ohsawa, M., Tanno, K., Sakata, K., Omama, S., Ishibashi, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081243 · Cited by 16
Metadata
- Authors
- Hijazi, Z., Wallentin, L., Siegbahn, A., Andersson, U., Christersson, C., Ezekowitz, J., Gersh, B. J., Hanna, M., Hohnloser, S., Horowitz, J., Huber, K., Hylek, E. M., Lopes, R. D., McMurray, J. J. V., & Granger, C. B.
- Affiliations
- Uppsala University (SE)
- University of Alberta (CA)
- Mayo Clinic (US)
- Bristol-Myers Squibb (United States) (US)
- Goethe University Frankfurt (DE)
- The University of Adelaide (AU)
- Wilhelminen Hospital (AT)
- Boston University (US)
- Western Infirmary (GB)
- Duke Medical Center (US)
- Corresponding author
- Hijazi, Ziad
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 61
- Issue
- 22
- Pages
- 2274-2284
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W189243586
- Cited by
- 231
- References
- 39
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 17 · 2023: 21 · 2022: 14 · 2021: 15 · 2020: 19 · 2019: 23 · 2018: 22 · 2017: 22 · 2016: 27 · 2015: 11 · 2014: 14 · 2013: 8
- FWCI
- 13.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- Bristol-Myers Squibb, Co.
- Pfizer Inc.
- Bristol-Myers Squibb Co.
- Boehringer-Ingelheim
- AstraZeneca, Merck/Schering-Plough, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline
- AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, Schering-Plough
- Boehringer-Ingelheim, AstraZeneca, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, and Schering-Plough/Merck
- AstraZeneca and Boehringer-Ingelheim
- Bristol-Myers Squibb/Pfizer
- Alere, AstraZeneca, Amgen, Abbott, Servier, Johnson & Johnson, Pfizer, and Bristol-Myers Squibb
- sanofi-aventis, St. Jude Medical, Boehringer-Ingelheim, Cardiome, Pfizer, Bayer, and Bristol-Myers Squibb
- sanofi-aventis, Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, Medtronic, and St. Jude Medical
- Bristol-Myers Squibb and Pfizer
- AstraZeneca, Bristol-Myers Squibb/Pfizer, Boehringer-Ingelheim, Bayer, Daiichi Sankyo, and sanofi-aventis
- Johnson & Johnson, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Pfizer, and Ortho-McNeil-Janssen
- Boehringer Ingelheim and Bayer
- Bristol-Myers Squibb, AstraZeneca, Boehringer-Ingelheim, and Daiichi Sankyo
- Bristol-Myers Squibb and Boehringer-Ingelheim
- Bristol-Myers Squibb, Boehringer-Ingelheim, Astellas, AstraZeneca, GlaxoSmithKline, Medtronic Foundation, Merck, sanofi-aventis, and the Medicines Company
- Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, AstraZeneca, Eli Lily, GlaxoSmithKline, Hoffman-La Roche, Novartis, Otsuka, Sanofi-Aventis, and the Medicines Company
- Pfizer, Novartis, Otsuka, and Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- atrial fibrillation, apixaban, stroke risk stratification, CHA2DS2-VASc score, cardiovascular mortality, systemic embolism, risk prediction, ARISTOTLE trial, warfarin, bleeding risk, biomarkers, prognosis, natriuretic peptides, cardiovascular risk
- MeSH terms
- Aged, Anticoagulants, Atrial Fibrillation, Embolism, Female, Fibrinolytic Agents, Humans, Male, Peptide Fragments, Prognosis, Pyrazoles, Pyridones, Warfarin, Biomarkers, Multivariate Analysis, Proportional Hazards Models, Risk Assessment, Natriuretic Peptide, Brain, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
